Expansion and Evaluation of AI-generated Clinical Assessment (AI-COA®) of Depression and Anxiety Severity

Inclusion criteria

• English fluency
• 18 to 65 years of age.
• HAM-D 17 > 10
• Starting, or has started, a new treatment for depression or anxiety within 2-3 weeks of enrollment
• Access to a laptop or other computer with a well functioning microphone and webcam, and a stable Internet connection
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Resides in the United States at the time of consent and during completion of study

Exclusion criteria

• Any cognitive impairment that limits ability to provide informed consent or authorization
• Vulnerable or protected populations (e.g. prisoners)
• Impairment that would prevent participants from completing an online survey and/or engaging in clinician assessment interviews (e.g., visual impairment, motor impairment, hearing impairment)
• Acute intoxication at the time of the assessments
• Concurrent medication/treatment:

• Receiving any fast-acting treatment for depression or anxiety (e.g. ketamine, psychedelics, deep brain stimulation, etc.) in between initial baseline assessment (A1) and Restest (A2) , or in between Follow up assessment (B1) and Retest (B2)
• Anxiolytics: Use of benzodiazepines or other anxiety-reducing medications that could affect speech or motor activity, within the past 4 weeks.
• Antipsychotics and Mood Stabilizers: Medications that can alter cognitive and motor functions, within the past 6 weeks.
• Stimulants: Use of medications like methylphenidate or amphetamines that affect energy levels and behavior, within the past 2 weeks
• Epilepsy medication: seizure activity or medication side effects that may alter behavior, within the past 4 weeks.
• Any history or evidence of any of the following conditions:

• Neurodevelopmental, Neurocognitive, Neurodegenerative or movement disorders including, but not limited to:
• Tourette's syndrome
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Parkinson's Disease
• Stroke
• Traumatic Brain Injury
• Facial paralysis.
• Conditions with vocal cord impact:

• Vocal cord injury or cerebrovascular accident or head trauma with residual dysarthria in the past year
• Disorders that may impact vocal cords such as acute or chronic laryngitis, vocal cord paresis or paralysis, or spasmodic dysphonia
• Past or active heavy smokers (an average of >20 cigarettes per day)
• Schizophrenia Spectrum and Other Psychotic Disorders:

• Individuals with a current or past diagnosis of Schizophrenia, Schizoaffective Disorder, or other psychotic disorders, including Delusional Disorder and Brief Psychotic Disorder.
• Current hypomanic episode as defined by DSM-5 criteria. This includes those with Bipolar I Disorder, Bipolar II Disorder, or Cyclothymic Disorder who are not in a stable mood state at the time of assessment.
• Chronic Pain Conditions: Such as fibromyalgia, which may affect facial expressions and vocal tone.
• Prosthetic Facial Devices: Could affect facial recognition algorithms. Cosmetic Procedures: Such as Botox injections or facelifts that can impact facial expressions.
• Dental Work: Major procedures that might affect speech.
• Participants who have previously participated in another research project by Deliberate.